-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-0217/S001 Personalized Tumor Vaccine in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-0217/S001 Personalized Tumor Vaccine in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-0217/S001 Personalized Tumor Vaccine in Solid Tumor Drug...
-
Track & Monitor
Precision and personalized medicine in pharma: personalized cancer vaccines
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s personalized cancer vaccines segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Borderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Borderline Personality Disorder (BPD) Clinical Trial Report Overview A total of 71 borderline personality disorder (BPD) clinical trials were conducted as of March 2024. The borderline personality disorder (BPD) clinical trial report provides a comprehensive understanding of the borderline personality disorder (BPD) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vafidemstat in Borderline Personality Disorder (BPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vafidemstat in Borderline Personality Disorder (BPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vafidemstat in Borderline Personality Disorder (BPD) Drug Details: Vafidemstat (ORY-2001)...
-
Analyst Opinions
Meeting the Needs of the Silver Segment in Personal Care
Meeting the Needs of the Silver Segment in Personal Care The phrase ‘silver (elderly) segment’ is defined as a distinct class of consumers, older than 55 years. According to GlobalData's macroeconomic data, accessed in November 2023, the Silver Generation consumers comprise 19% of the world population, of which women constitute over half of the older population. However, there are regional and country-level differences in the aging population demographics. Western European countries such as France and Germany, are among the top...
-
Sector Analysis
United Kingdom (UK) General Insurance Market Essentials (Personal and Commercial Lines) and Distribution, H2 2023 Update
United Kingdom (UK) General Insurance Market Report Overview In 2022, both personal lines and commercial lines experienced growth and contributed to an overall growth rate of the total insurance market. Notably, personal lines outperformed commercial lines when it came to their individual market growth. Strong performances by personal and commercial insurance lines and increasing premiums aided the UK insurance market growth in 2023. Rising inflation and disruptions in the supply chain led to increased claim costs for insurers in 2023....
-
Sector Analysis
NewSpain Retail Consumer Insights – Spending Intentions and Shopping Habits, 2024
This report provides detailed consumer insights into Spain's retail market. It focuses on the economy, consumer sentiment towards personal finances, cost pressures, offline retail, and online retail. Spanish consumers remain hopeful about their personal finances despite expecting the economy to worsen over the short term. Despite this, 59.0% plan to cut back on non-essential retail spending in the next six months, while essentials like food and health see less impact. Older generations, particularly Gen X and Boomers, are more pessimistic...
-
Company Insights
NewGrupo Financiero Banorte – Digital Transformation Strategies
This report provides insight into Banorte's fintech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts. Grupo Financiero Banorte SAB de CV (GFNorte) is a financial services group, which offers a range of banking and related financial solutions. It offers retail and commercial banking, brokerage, retirement and insurance solutions, asset management, and other solutions. The product portfolio includes savings, checking and payroll accounts; mortgage; debit and credit card;...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-4157 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-4157 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-4157 in Gastric Cancer Drug Details: mRNA-4157 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-4157 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-4157 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-4157 in Pancreatic Ductal Adenocarcinoma Drug Details: mRNA-4157 is under...